Table 2.
Use of eculizumab for prevention of aHUS on patients after kidney transplantation.
| Authors, Publication Year | Type of Study | Ktx Patients Received prophylaxis with Ecu, n | Median Age at Ktx, Months |
Female, n | Patients with Prior Failed Ktx, n | Type of Donor | Ecu Initiation, Median Days (D) |
Duration of Therapy, Months | PLEX, % | Mean Follow up, Months | aHUS/ TMA Recurrence after Ecu, n | Graft Loss, n | Acute Rejection, n |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Levi et al., 2017 | Case series | 10 | 41 | 5 | 4 | DD, 7 | D 0 | Ecu cont. a | 0 | 21 | 1 b | 1 | AMR, 2 |
| LD, 3 | |||||||||||||
| Sheerin et al., 2015 | Retrospective Cohort | 8 | - | - | - | - | - | - | - | - | 0 | 0 | - |
| Matar et al. 2014 | Retrospective Cohort | 4 | 39 | 3 | 3 | LD, 1 | D −1 | 6 c | 0 | 20.5 | 0 | 0 | 0 |
| Zuber et al., 2012 | Retrospective multicenter cohort | 9 | 25.6 | - | - | DD, 3 | D 5, 1 | Ecu cont. | 66 | 14.5 | 0 | 1 d | AMR + |
| D 0, 2 | ACR, 1 | ||||||||||||
| Modelli de Andrade et al., 2017 | Prospective cohort | 2 | 29 | 1 | - | DD, 1 | D 0 | Ecu cont. | 0 | 4 | 0 | 1 e | - |
| Zuber et al., 2017 | Multicenter retrospective cohort | 35 | - | 63 | - | - | D 0 | - | 0 | 35 | 17 | 1 | - |
| Bresin et al., 2013 | Case series from 4 independent multinational cohorts | 4 | - | - | - | - | - | - | - | - | 0 | 0 | - |
| Kumar et al., 2016 | Case series | 9 | - | 8 | - | LU, 7 | - | - | - | 31.2 | 0 | 0 | 0 |
| DD, 2 | |||||||||||||
| Yelken et al. 2017 | Retrospective single center cohort | 7 | - | - | - | - | - | - | - | 28 | 0 | 0 | |
| Favi et al., 2017 | Retrospective single center cohort | 12 | - | - | - | - | - | - | - | 26.5 | 0 | 1 | 3 |
| Comparison group with no Ecu | 24 | - | - | - | - | - | - | - | 79 | 11 | 7 | 7 | |
| Siedlecki et al. 2019 | Multicenter cohort | 88 | 32.3 | 45 | 24 | - | - | Ecu cont. | - | 27 | - | 3 | - |
(-) missing information from the original study. a. One patient was discontinued at 28.7 m with no complement mutation identified. b. One patient had recurrence after discontinuation followed by graft loss. There were subclinical TMA lesions on kidney biopsy in 2 patients. c. One patient continued prophylaxis at the time of Matar et al. 2014 publication. d. Patient had immediate graft loss due to intestinal hemorrhage. e. Patient had intestinal hemorrhage at 4 m after kidney transplantation. Abbreviations: Ktx: Kidney transplantation; n: Number; Ecu: Eculizumab cont.: Continued; D: Day; DD: Deceased donor; LD: Living donor; LU: Living unrelated donor; AMR: Antibody mediated rejection; ACR: Acute cellular rejection.